CY2501B1 - Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents. - Google Patents

Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents.

Info

Publication number
CY2501B1
CY2501B1 CY0500008A CY0500008A CY2501B1 CY 2501 B1 CY2501 B1 CY 2501B1 CY 0500008 A CY0500008 A CY 0500008A CY 0500008 A CY0500008 A CY 0500008A CY 2501 B1 CY2501 B1 CY 2501B1
Authority
CY
Cyprus
Prior art keywords
benzodioxane
benzodioxole
dihydrobenzofuran
benzofuran
melatonergic agents
Prior art date
Application number
CY0500008A
Other languages
English (en)
Inventor
John D Catt
Graham Johnson
Daniel J Keavy
Ronald J Mattson
Michael F Parker
Katherine S Takaki
Joseph P Yevich
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CY2501B1 publication Critical patent/CY2501B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polyesters Or Polycarbonates (AREA)
CY0500008A 1996-12-10 2005-01-31 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents. CY2501B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10

Publications (1)

Publication Number Publication Date
CY2501B1 true CY2501B1 (en) 2005-09-02

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500008A CY2501B1 (en) 1996-12-10 2005-01-31 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents.

Country Status (26)

Country Link
US (3) US5856529A (cs)
EP (1) EP1027043B1 (cs)
JP (1) JP4290765B2 (cs)
KR (1) KR100499106B1 (cs)
CN (1) CN1152679C (cs)
AR (1) AR010346A1 (cs)
AT (1) ATE281833T1 (cs)
AU (1) AU719994B2 (cs)
BR (1) BR9713690B1 (cs)
CA (1) CA2274183C (cs)
CY (1) CY2501B1 (cs)
CZ (1) CZ297673B6 (cs)
DE (1) DE69731562T2 (cs)
DK (1) DK1027043T3 (cs)
ES (1) ES2230626T3 (cs)
HK (1) HK1029947A1 (cs)
HU (1) HU226524B1 (cs)
IL (1) IL129999A (cs)
NO (1) NO321450B1 (cs)
NZ (1) NZ335910A (cs)
PL (1) PL190499B1 (cs)
PT (1) PT1027043E (cs)
RU (1) RU2190609C2 (cs)
TW (1) TW476758B (cs)
WO (1) WO1998025606A1 (cs)
ZA (1) ZA9711051B (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
EP1082115A4 (en) * 1998-06-05 2002-10-24 Bristol Myers Squibb Co MELATONERGICS BASED ON HETEROCYCLIC CIS DERIVATIVES OF CYCLOPROPANE
DK1189900T3 (da) * 1999-06-30 2004-04-26 Bristol Myers Squibb Co Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
KR100654516B1 (ko) 2001-05-15 2006-12-05 에프. 호프만-라 로슈 아게 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체
WO2003029238A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
WO2004005266A1 (en) * 2002-07-03 2004-01-15 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
CA2495942C (en) * 2002-08-30 2010-03-23 F. Hoffmann-La Roche Ag Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
MXPA05002704A (es) * 2002-09-12 2005-05-05 Hoffmann La Roche Compuestos de acido n-sustituido-1h-indol-5-propionico como agonistas de los receptores activados proliferadores de peroxisomas (ppar) utiles para el tratamiento de diabetes.
ES2312819T3 (es) * 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
US7145478B2 (en) * 2002-12-17 2006-12-05 Evolution Robotics, Inc. Systems and methods for controlling a density of visual landmarks in a visual simultaneous localization and mapping system
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0712014A2 (pt) * 2006-05-22 2011-12-27 Vanda Pharmaceuticals Inc tratamento de distérbios depressivos
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
JP5289308B2 (ja) * 2007-04-26 2013-09-11 武田薬品工業株式会社 二環性化合物およびその医薬用途
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
CA3159584A1 (en) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (en) * 2009-07-29 2011-02-23 V.Mane Fils New bicyclic dioxanes, their preparation and their use as organoleptic compounds
SI2626350T1 (sl) * 2010-09-22 2015-09-30 Eisai R&D Management Co., Ltd. Spojina ciklopropana
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
KR102411809B1 (ko) 2012-01-26 2022-06-22 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP2855424B1 (en) * 2012-05-18 2017-10-11 Vanda Pharmaceuticals Inc. Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
WO2014010603A1 (ja) 2012-07-10 2014-01-16 アステラス製薬株式会社 腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物、及び該医薬組成物に含有される化合物のスクリーニング方法
EP3767297A1 (en) 2012-12-18 2021-01-20 Vanda Pharmaceuticals Inc. Method of determining tau and thereby determining whether a patient has a free-running circadian rhythm
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
WO2015047113A1 (en) * 2013-09-30 2015-04-02 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as η1-receptor antagonists
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3105212A1 (en) 2014-02-12 2016-12-21 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
EP4137129A1 (en) 2014-09-02 2023-02-22 Vanda Pharmaceuticals Inc. Tasimelteon for treating smith-magenis syndrome
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯（大连）医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
CN109310638A (zh) 2016-05-06 2019-02-05 医师印章有限责任公司 缬草组合物和相关方法
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
EP3661494B8 (en) 2017-08-02 2023-11-22 Vanda Pharmaceuticals Inc. Use of tasimelteon for the treatment of affective disorders in majority black african patients
KR20240007693A (ko) 2018-03-04 2024-01-16 반다 파마슈티칼즈, 인코퍼레이티드. 타시멜테온을 이용한 질환의 치료
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
CN114641284A (zh) 2019-06-29 2022-06-17 万带兰制药公司 他司美琼在治疗睡眠异常中的应用
KR102650321B1 (ko) 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
BR9708949A (pt) * 1996-05-14 1999-08-03 Glaxo Group Ltd Composto formulação farmacêutica e processos de preparação dos mesmos e de tratamento de um mamífero incluindo o homem

Also Published As

Publication number Publication date
AU719994B2 (en) 2000-05-18
AU5598598A (en) 1998-07-03
ATE281833T1 (de) 2004-11-15
JP4290765B2 (ja) 2009-07-08
JP2001505916A (ja) 2001-05-08
TW476758B (en) 2002-02-21
DE69731562D1 (de) 2004-12-16
PL190499B1 (pl) 2005-12-30
ZA9711051B (en) 1999-06-09
US6060506A (en) 2000-05-09
EP1027043A1 (en) 2000-08-16
IL129999A0 (en) 2000-02-29
HUP0000695A3 (en) 2002-09-30
CN1152679C (zh) 2004-06-09
HUP0000695A2 (hu) 2001-05-28
DK1027043T3 (da) 2005-01-10
HU226524B1 (en) 2009-03-30
NO992804D0 (no) 1999-06-09
NO321450B1 (no) 2006-05-15
ES2230626T3 (es) 2005-05-01
KR20000069396A (ko) 2000-11-25
BR9713690B1 (pt) 2009-08-11
CA2274183A1 (en) 1998-06-18
WO1998025606A1 (en) 1998-06-18
CN1239886A (zh) 1999-12-29
PL333950A1 (en) 2000-01-31
CZ199199A3 (cs) 1999-09-15
RU2190609C2 (ru) 2002-10-10
DE69731562T2 (de) 2005-11-24
KR100499106B1 (ko) 2005-07-01
BR9713690A (pt) 2000-05-02
CZ297673B6 (cs) 2007-02-28
EP1027043B1 (en) 2004-11-10
US5856529A (en) 1999-01-05
CA2274183C (en) 2006-10-24
EP1027043A4 (en) 2002-02-20
AR010346A1 (es) 2000-06-07
NO992804L (no) 1999-08-09
PT1027043E (pt) 2005-02-28
US5981571A (en) 1999-11-09
NZ335910A (en) 2000-11-24
HK1029947A1 (en) 2001-04-20
IL129999A (en) 2004-06-20

Similar Documents

Publication Publication Date Title
CY2501B1 (en) Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents.
ZA9811081B (en) (Benzodioxan, Benzofuran or Benzopyran) Derivatives having fundic relaxation properties.
ID22271A (id) Turunan-turunan 2-(purin-9-il) tetrahidrofuran-3,4-diol
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
PH31295A (en) Ä(Benzodioxan, benzofuran or benzopyran)alkylaminoÜalkyl substituted guanidines.
HK1018901A1 (en) Benzofurans and benzopyrans as chronobiological agents
ZA200000865B (en) Dicarboalkoxy dioxolanes.
ATE203528T1 (de) Antineurodegenerativ wirksame 10-aminoaliphatyl- dibenz- b,f oxepine
DE59902921D1 (en) Substituierte alpha,beta-anellierte butyrolactone
ZA991270B (en) Method of improving paper conversion capability, sizing agent therefor and paper so made.
HUP0104510A3 (en) Benzofuran derivatives, their preparation and use
YU10499A (sh) Supstituisani 1,2,3,4-tetrahidro-2-dibenzofuranamini i 2-aminociklohepta /b/benzofurani
ITTO960041A0 (it) Macchina semovente per la stabilizzazione, mediante martellinatura e compattazione, di binari posati su massicciata.
AP2000001730A0 (en) 2,4,4-Trisubstituted-1,3-dioxolane antifungals
NL1004459A1 (nl) Geluidwerende elementen.
IL126780A0 (en) Substituted 1,3-benzodioxoles
ES1035719Y (es) Pantalla de proteccion facial, desechable.
ZA200103987B (en) Benzofuran derivatives, their preparation and use.
IE900043L (en) Substituted indole, benzofuran and benzothiophenes.
SI0901483T1 (en) Benzofurans and benzopyrans as chronobiological agents
ES1037296Y (es) Juego de construccion, dinamico.
ZA974375B (en) Benzofuran carboxamides and their therapeutic use.
HK1030940A1 (en) Method for the preparation of citalopram.
HK1065997A1 (en) Method for the preparation of citalopram.
ES1035160Y (es) Estructura de contencion y revestimiento de taludes constituida por neumaticos.